首页> 外国专利> EVALUATING EFFICACY OF H-4 COMPOUND AEROSOL NEBULIZATION IN SPUTUM POSITIVE TUBERCULOSIS SUBJECTS (INCLUDING NEWLY DIAGNOSED amp; EXTENSIVE DRUG RESISTANCE TUBERCULOSIS) -A OPEN LEVEL PILOT CLINICAL STUDY

EVALUATING EFFICACY OF H-4 COMPOUND AEROSOL NEBULIZATION IN SPUTUM POSITIVE TUBERCULOSIS SUBJECTS (INCLUDING NEWLY DIAGNOSED amp; EXTENSIVE DRUG RESISTANCE TUBERCULOSIS) -A OPEN LEVEL PILOT CLINICAL STUDY

机译:H-4复合气雾剂在痰阳性结核病患者(包括新诊断和广泛耐药性结核病)中的评估疗效-公开的中试临床研究

摘要

Aerosol prepared by the hydroalcoholic extract of H-4 compound (having Dalchini, Tejpatra, Lavang and Talishapatra in the ratio of 4:2:1:1) given through nebulization machine twice in a day in the dose of 2.5ml for 10 days completely convert sputum positive tubercular patients into sputum negative for AFB, relive the symptoms of tuberculosis in newly diagnosed cases and its use for 10 days help in regenerating lung parenchyma as evidenced by radiological changes. This drug along with some oral Ayurvedic medicines can be successfully used for the management of newly diagnosed sputum positive tubercular subjects without using any conventional anti-tubercular drug. Aerosol prepared by hydroalcoholic extract of H-4 compound and Shirisha (Albizzia lebback) given through nebulizer machine in the dose of 3ml (1.5ml + 1.5ml) for 10 days converts extensive drug resistance sputum positive tubercular patients to sputum negative for AFB and significantly reduce the presenting symptoms including cough, dyspnea, expectoration and chest pain. The drug is clinically proven to have anti-tubercular property. Inventor: Dr. Divya Kajaria, Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi. Assignee: Dr. Divya Kajaria, Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi.
机译:由H-4化合物的水醇提取物(Dalchini,Tejpatra,Lavang和Talishapatra的比例为4:2:1:1)制成的气雾剂,每天两次通过雾化机以2.5ml的剂量连续10天给药将痰阳性的结核病患者转化为AFB阴性的痰液,重新诊断新诊断病例的结核病症状,如放射学改变所证明的那样,将其使用10天有助于肺实质的再生。该药物与一些口服阿育吠陀药物一起可以成功用于新诊断的痰阳性结核病患者的治疗,而无需使用任何常规的抗结核药物。由H-4化合物的水醇提取物和Shirisha(Albizzia lebback)通过喷雾器给予的剂量为3ml(1.5ml + 1.5ml)的喷雾剂制备10天,将广泛耐药的痰阳性结核病患者转化为AFB阴性的痰,并且显着减少出现的症状,包括咳嗽,呼吸困难,吐痰和胸痛。该药物已被临床证明具有抗结核特性。发明人:新德里阿育吠陀全印度研究所Kayachikitsa系Divya Kajaria博士。受让人:新德里阿育吠陀全印度研究所Kayachikitsa系Divya Kajaria博士。

著录项

  • 公开/公告号IN201811009523A

    专利类型

  • 公开/公告日2018-03-30

    原文格式PDF

  • 申请/专利权人

    申请/专利号IN201811009523

  • 发明设计人 DIVYA KAJARIA;

    申请日2018-03-15

  • 分类号C12Q1/6883;

  • 国家 IN

  • 入库时间 2022-08-21 12:51:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号